The new director of National Institute of Allergy and Infectious Diseases (NIAID), Dr. Jeanne Marrazzo joined AVAC Executive Director in conversation.
Avac Event
AVAC in Conversation with NIAID’s Jeanne Marrazzo
Avac Event
The Adolescent Medicine Trials Network (ATN): Research addressing HIV health inequities among US adolescents and young adults
Join us for an overview of the newest cycle of the Adolescent Medicine Trials Network! This webinar will highlight ATN 165: Linking Youth to PrEP Services (LYPS) which tests an innovative mobile delivery and mHealth intervention to optimize PrEP adherence and persistence among sexual minority men, ATN 167: Legal, Economic, and Affirming Peer Support (LEAP) for transgender and gender diverse youth, and how the network prioritizes and amplifies the voices of youth directly impacted by the ATN’s pivotal research.
Speakers Include:
- Dr. Lisa Hightow-Weidman, ATN Principal Investigator, College of Nursing Florida State University
- Dr. Sybil Hosek, ATN Principal Investigator, University of Illinois-Chicago
- Dr. Sari Reisner, University of Michigan School of Public Health
- Dr. Kristi Gamarel, University of Michigan School of Public Health
- Dr. Kate Muessig, Florida State University
- Dr. Audrey Pettifor, University of North Carolina at Chapel Hill
- Zoe Njemanze, ATN Subject Matter Research Consultant
- Kendrick Forte, ATN Subject Matter Research Consultant
- Rodrigo Cabrera, ATN National Community Advisory Board
Avac Event
Cervical Cancer Awareness Month Webinar Series (Jan 11 to Feb 1)
Webinar 1: Cervical Cancer: What, where, and prevention and treatment options
Thursday January 11, 8:00AM/4:00PM EAT
This webinar provided an overview of cervical cancer including what cervical cancer is, who is impacted, and prevention and treatment options.
Speakers included: Helen Kelly, Shona Dala, and Maribel Almonte Pacheco, WHO and Michelle Chevalier, US Department of State—Bureau of Global Health Security & Diplomacy/PEPFAR
Recording / Helen Kelly Slides
Webinar 2: Advocacy and Cervical Cancer: Voices that are creating change
Thursday January 18, 8:00AM/4:00PM EAT
During this webinar, we heard from advocates on how they have used their voice to bring more attention to cervical cancer and its impact on communities.
Speakers include: Tamika Felder, Cervivor and Karen Nakawala, Teal Sisters Foundation Zambia
Recording / Tamika Felder Slides / Karen Nakawala Slides
Webinar 3: Screening and Treating Cervical Cancer
Thursday January 25, 8:00AM/4:00PM EAT
During this webinar, speakers discussed options for screening and treating cervical cancer along with ongoing research.
Speakers include: Fred Wyand, American Sexual Health Association/National Cervical Cancer Coalition and Bothwell Guzha, University of Zimbabwe
Recording / Fred Wyand Slides / Bothwell Guzha Slides
Webinar 4: Cervical Cancer Among Key Populations
Thursday February 1, 8:00AM/4:00PM EAT
This webinar explored how cervical cancer impacts key populations and those vulnerable to HIV infections.
Speakers include: Samiya Mahmoud, Association for the Prevention of Septic Abortion, Bangladesh (BAPSA) and Shona Dalal, Helen Kelly, WHO
New Year, New PrEPWatch Resources
In 2024 we look forward to continuing to provide advocates with tools to support our collective work to ensure access to PrEP in all its forms to all who can benefit from it.
PrEPWatch.org has grown significantly in the past year, reaching a growing number of implementers, policy makers and advocates with continually updated tools and information that are instrumental to delivering the growing range of HIV prevention options. Throughout 2023, visitors from every country in the world have used PrEPWatch.org, a one-stop online clearinghouse of data, guidelines, tracking tools and other resources to help the global community speed the delivery of every proven method of PrEP to everyone who needs it. Check out what’s new and updated on PrEPWatch.org!
New on PrEPWatch
Modelling the Scale-Up of Injectable CAB for PrEP
Our Biomedical Prevention Implementation Collaborative (BioPIC) teamed up with the HIV Modelling Consortium to produce this analysis of the potential impact of scaling up injectable cabotegravir (CAB) for PrEP, What can modelling tell us about the scale-up of CAB for PrEP? The findings can help implementers and policymakers understand what to expect and guide early policy decisions to maximize the impact of CAB for PrEP on the HIV epidemic.
Country Pages
PrEPWatch has added 35 new country pages where you can find the status of drug registration for PrEP products, data on PrEP initiations by product, country-level PEPFAR targets, and links to key policy documents and guidelines.
The Integrated Study Dashboard
Produced under the BioPIC project, the Integrated Study Dashboard tracks all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new biomedical HIV PrEP options, including CAB for PrEP and the dapivirine vaginal ring (DVR), and has been recently expanded to include links to study results and study websites. The dashboard is updated in real time, and links to results will be added as they become available.
More Essential Resources on PrEPWatch.org
Tracking Country Planning for Product Introduction
The Country Planning for Product Introduction Matrix tracks key indicators for the introduction of injectable CAB and the DVR by country, including regulatory status, late-stage clinical trials and implementation research, procurement plans, and recent oral PrEP provision.
Training PrEP Champions
Among the most popular resources on PrEPWatch, the HIV Prevention Ambassador Training Package and Toolkit prepares potential and current PrEP users to be leaders – and “Ambassadors” – in the rollout of PrEP for HIV prevention in their communities. Developed as part of the MOSAIC project, it includes a training manual and resources for Ambassadors to use in peer outreach and community education.
Trends in PrEP Initiations
The Global PrEP Tracker provides quarterly updates on global trends in PrEP initiation by geography, delivery models, and more. The Global PrEP Tracker has become an indispensable resource for following the state of the field in delivering PrEP.
We hope these tools, created through strong partnerships and joint effort, support your work to accelerate the delivery of HIV prevention options. We are always interested in collaboration to ensure needed resources are developed and up to date. If you have information to share or resource needs, please let us know by reaching out to janki@avac.org and catherine@avac.org.
Avac Event
African Workshop on HIV & Women 2024
The inaugural edition of the African Workshop on HIV & Women will take place in hybrid format on 22 – 23 February 2024 in Nairobi, Kenya.
The time zone that will be used for this meeting is East Africa Time (EAT). If you need to convert the times to your timezone, this website might be of interest to you: www.WorldTimeBuddy.com.
This exciting new initiative is a regional workshop paired to the annual “International Workshop on HIV & Women”. It is an outstanding opportunity for both local and international healthcare providers, researchers, government, industry, and community representatives to discuss and further increase their knowledge on the issues related to HIV and women living in Africa.
The primary purpose of this workshop is to support changes that will provide a better quality of life for women living with HIV and reduce HIV transmissions in the region.
The format of the workshop enables attendees to learn from renowned HIV experts, discuss challenges, gaps, and opportunities for further learning and research. The debates and roundtables are an especially important vehicle to discuss issues and challenge dogma.
The workshop also provides a forum for early-career investigators to present their research and to personally meet with experts they view as mentors and inspiration for their work.
The meeting organizers hope this workshop will catalyze forming a community, where attendees continue to participate yearly and form valuable relationships and partnerships that lead to collaborative projects and positive changes.
Regular fee deadline, February 8.
Avac Event
PrEPVacc: An in-depth look at the trial, and what’s next
During this webinar, the PrEPVacc team and AVAC reviewed the status of the PrEPVacc trial. PrEPVacc, a 3-in-1 trial testing two different vaccine candidates (plus placebo arm) and two daily oral PrEP regimens, recently discontinued vaccinations in the trial due to an independent data review board’s conclusion that the vaccines were having no effect in preventing HIV infection. On this call, we will review key aspects of PrEPVacc, including its innovative study design, implementation, integrated social science, and data analysis plans. Speakers engaged in conversation about what we’ve learned from PrEPVacc, what we can still learn, and what this may mean for the HIV prevention field.
- PrEPVacc Trial Design: Sheena McCormack, PrEPVacc Project Lead, MRC Clinical Trials Unit, University College London, UK
- Trial Implementation and Baseline Data: Eugene Ruzagira, PrEPVacc Trial Director, MRC/UVRI & LSHTM Uganda Research Unit
- Integrated Social Science: Rachel Kawuma, PrEPVacc Social Scientist, MRC/UVRI & LSHTM Uganda Research Unit
- Analysis Plan: Sheila Kansiime, PrEPVacc Statistician, MRC/UVRI & LSHTM Uganda Research Unit
Recording / Sheena McCormack Slides / Eugene Ruzagira Slides / Rachel Kawuma Slides / Sheila Kansiime Slides
Avac Event
Reporting the African Science Story: Decoding scientific research to support public health in Africa
Eastern time zone
Generating compelling and nuanced media stories on health and science depends on strong connections between researchers and providers, journalists reporting the story, and civil society and community members who have critical perspectives to share. Researchers need skills to explain science in plain language and be open to questions. Civil society and affected communities are also a crucial component to strong news coverage, providing advocacy perspectives that capture the full impact of a given issue.
Since 2012, AVAC has worked to support health journalist associations in East and Southern Africa to strengthen the capacity of journalists to report on HIV prevention research. In 2020, AVAC expanded this work to include COVID science. Through the Media Science Café Program, AVAC partners with health media associations in Kenya, Tanzania, Uganda, Zambia and Zimbabwe to bring journalists together with researchers, implementers, civil society, policy makers, regulators and policy makers to build relationships that will foster accurate reporting of HIV, COVID and other science or health stories in those countries.
The monthly cafés are structured as informal meetings with 20-30 journalists and expert speakers. Experts in the field gather to present and discuss timely health topics.
Moderators: Kay Marshall, AVAC Zarina Geloo, Zambia Media Cafe Convener
Speakers: Esther Nakkazi, Uganda Media Cafe Convener Anna Miti, Zimbabwe Media Cafe Convener
Px Pulse: A season of listening
As we look ahead to 2024 and the vital work AVAC and partners will be carrying forward, the conversations from 2023 offer guidance and insights. Px Pulse, AVAC’s podcast on critical issues facing HIV prevention research, hosted several not-be-missed conversations in 2023 that will reverberate into the year ahead.
From a stalled PEPFAR reauthorization to LGBTQIA+ voices fighting persecution in Uganda; from efforts to bring equity to a new global architecture for pandemic readiness to advances in HIV vaccine science and advocacy to include pregnant people in research—we hope that all of these conversations can inform our advocacy in 2024. Click on the episode for both recordings and resources.
PEPFAR at 20: Keeping the promise (23:16)
Considered one of the greatest US foreign policy and global development achievements of the century, the program has saved upwards of 25 million lives since it launched in 2003. But PEPFAR is marking its 20th anniversary while fighting for its future. LISTEN HERE.
LGBTQIA+ Advocacy in Uganda: Facing down fear and fighting for justice (24:19)
In March 2023, the Ugandan Parliament moved forward broad-reaching legislation to further criminalize LGBTQIA+ people. This podcast features Ugandan advocates and AVAC partners discussing the specifics of how these attacks have gained momentum and their ties to US-based religious extremists. The advocates discuss what needs to happen next. LISTEN HERE.
The Shape of Pandemic Preparedness is Being Decided. Now is the Time for Collective Action (15:14)
Health leaders around the world are in the midst of creating a new architecture to deal with pandemics. Chris Collins, the CEO and President at Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, talks about what’s at stake, which policymakers get it already, why this year matters so much, and what advocates can do about it. LISTEN HERE.
PPPR Advocacy 101: Find out what it means to you (19:05)
Over the coming months, global leaders will make key decisions about several initiatives to prepare for the next pandemic. This podcast explores what they commit to, how much they will spend and how well these plans safeguard equity. LISTEN HERE.
Inclusion of Pregnant and Lactating People in HIV Research: What you need to know (34:28)
AVAC’s Manju Chatani-Gada takes us through conversations with a trial participant who became pregnant, researchers, policymakers and donors to understand why this population gets excluded, the impact it has and what to do about it. LISTEN HERE.
Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why? (21:23)
Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why? Dr. Katy Stephenson explores the implications of recent trial results, the big questions driving next generation vaccine development, and new strategies underway in early phase research. LISTEN HERE.
Happy listening—and let us know what topics you want to hear more about in 2024!
The Search for an HIV Vaccine Must Continue
Field Will Learn for Halted PrEPVacc Arm
By Jeanne Baron
Today the PrEPVacc trial team announced at a special session at the International Conference on AIDS and STIs in Africa (ICASA) in Harare, Zimbabwe, that they were stopping vaccinations in the study following a review by an independent data safety committee that determined there was little chance the vaccines being tested could stop HIV acquisition. The oral PrEP arms of the study will continue.
PrEPVacc was testing two different vaccine strategies against a placebo: one regimen combining a DNA vaccine with a protein-based vaccine (AIDSVAX), and another regimen combining DNA, MVA and a protein-based vaccine (CN54gp140).
“We always hope for a positive outcome in HIV prevention trials, and this news is disappointing,” said Mitchell Warren, AVAC executive director. “We look forward to seeing the full PrEPVacc data in 2024 and hope it will add to the body of evidence that is helping scientists understand how to develop better vaccine candidates that will one day protect against HIV.”
“The PrEPVacc outcome underscores yet again that the science of HIV vaccine development is extremely challenging,” he added. “Now is not the time to step back from vaccine research. There are several promising strategies in early-stage research that must continue, along with research for other HIV prevention options. We will not end HIV without ensuring that everyone who is vulnerable to HIV infection has a choice of effective and desirable prevention options.”
Importantly, PrEPVacc’s PrEP arms will continue. The study is testing two different formulations of daily oral PrEP, looking to see if a new formulation – F/TAF (also known as Descovy) – is at least as good in the trial population at protecting against HIV acquisition as F/TDF (also known as Truvada and the most widely used version of PrEP). The trial will provide the first data for F/TAF among cisgender women (who make up 87% of the just over 1,500 PrEPVacc trial participants). F/TAF is approved for use in the US and UK, but not for those individuals who have receptive vaginal sex, since previous trials regrettably did not enroll cisgender women.
The PrEPVacc study is scheduled to conclude in 2024 and data from all arms of the study are expected to be reported in the last half of 2024.
“The PrEP arms of PrEPVacc will provide important insights into the potential of expanding access of F/TAF for PrEP to women in East and Southern Africa who need additional options to protect themselves from HIV. Equitable access to new interventions should be a goal of every research program,” said Stacey Hannah, AVAC’s director of Research Engagement.
“PrEPVacc is a complex, innovative trial design, and, while the vaccine result today is disappointing, the trial team has worked from the outset to implement the Good Participatory Practice (GPP) Guidelines. The team’s hard work on the front-end to apply GPP to this trial is paying off especially now in the ability to deliver complex, disappointing results to trial participants, advocates, policymakers and other key supporters of PrEPVacc and of HIV prevention broadly.”
Press Release
The Search for an HIV Vaccine Must Continue
Field Will Learn for Halted PrEPVacc Arm
New York, 6 December 2023 – Today the PrEPVacc trial team announced at a special session at the International Conference on AIDS and STIs in Africa (ICASA) in Harare, Zimbabwe, that they were stopping vaccinations in the study following a review by an independent data safety committee that determined there was little chance the vaccines being tested could stop HIV acquisition. The oral PrEP arms of the study will continue.
PrEPVacc was testing two different vaccine strategies against a placebo: one regimen combining a DNA vaccine with a protein-based vaccine (AIDSVAX), and another regimen combining DNA, MVA and a protein-based vaccine (CN54gp140).
“We always hope for a positive outcome in HIV prevention trials, and this news is disappointing,” said Mitchell Warren, AVAC executive director. “We look forward to seeing the full PrEPVacc data in 2024 and hope it will add to the body of evidence that is helping scientists understand how to develop better vaccine candidates that will one day protect against HIV.”
“The PrEPVacc outcome underscores yet again that the science of HIV vaccine development is extremely challenging,” he added. “Now is not the time to step back from vaccine research. There are several promising strategies in early-stage research that must continue, along with research for other HIV prevention options. We will not end HIV without ensuring that everyone who is vulnerable to HIV infection has a choice of effective and desirable prevention options.”
Importantly, PrEPVacc’s PrEP arms will continue. The study is testing two different formulations of daily oral PrEP, looking to see if a new formulation – F/TAF (also known as Descovy) – is at least as good in the trial population at protecting against HIV acquisition as F/TDF (also known as Truvada and the most widely used version of PrEP). The trial will provide the first data for F/TAF among cisgender women (who make up 87% of the just over 1,500 PrEPVacc trial participants). F/TAF is approved for use in the US and UK, but not for those individuals who have receptive vaginal sex, since previous trials regrettably did not enroll cisgender women.
The PrEPVacc study is scheduled to conclude in 2024 and data from all arms of the study are expected to be reported in the last half of 2024.
“The PrEP arms of PrEPVacc will provide important insights into the potential of expanding access of F/TAF for PrEP to women in East and Southern Africa who need additional options to protect themselves from HIV. Equitable access to new interventions should be a goal of every research program,” said Stacey Hannah, AVAC’s director of Research Engagement.
“PrEPVacc is a complex, innovative trial design, and, while the vaccine result today is disappointing, the trial team has worked from the outset to implement the Good Participatory Practice (GPP) Guidelines. The team’s hard work on the front-end to apply GPP to this trial is paying off especially now in the ability to deliver complex, disappointing results to trial participants, advocates, policymakers and other key supporters of PrEPVacc and of HIV prevention broadly.”
###
About AVAC
AVAC is an international non-profit organization that provides an independent voice and leverages global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention options, as part of a comprehensive and integrated pathway to global health equity. Follow AVAC on Twitter @HIVpxresearch; find more at www.avac.org and www.prepwatch.org.